Sign inJoin waitlistJoin the waitlist

JP

Jeremy Perkins

Associate Professor, Medicine, School of Medicine · National Capital Consortium

Credentials: · · ·

History

National Capital Consortium
Present

NCC Hematology-Medical Oncology 2000-
2000–2003
Internal Medicine
1997–2000
Uniformed Services Univ of the Hlth Sci, F Edward Hebert Sch of Med
1993–1997
US Military Academy at West Point 1993
1989–1993

Research

The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital
The Journal of trauma · 2007 · 1,124 citations
Damage control resuscitation: directly addressing the early coagulopathy of trauma
The Journal of trauma · 2007 · 996 citations
Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients
Annals of Surgery · 2008 · 792 citations

John Holcomb
22 papers
Philip Spinella
16 papers
Alec Beekley
13 papers
KG
Kurt Grathwohl
13 papers · 1 as a resident
AC
Andrew Cap
7 papers · 2 as a fellow
LB
Lorne Blackbourne
7 papers
James Sebesta
6 papers
MS
Martin Schreiber
6 papers
Donald Jenkins
5 papers
Thomas Repine
5 papers
Andrew Shorr
4 papers
Brian Eastridge
4 papers

Clinical trials

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
Site PI · Recruiting
Henry M. Jackson Foundation for the Advancement of Military Medicine
2025–2028
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033